These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 38172019)
1. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan. Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691 [TBL] [Abstract][Full Text] [Related]
3. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine. Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Pellissier JM; Brisson M; Levin MJ Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938 [TBL] [Abstract][Full Text] [Related]
7. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911 [TBL] [Abstract][Full Text] [Related]
8. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Sanford M; Keating GM Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941 [TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Klein NP; Bartlett J; Fireman B; Marks MA; Hansen J; Lewis E; Aukes L; Saddier P Vaccine; 2019 Aug; 37(36):5422-5427. PubMed ID: 31301920 [TBL] [Abstract][Full Text] [Related]
10. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination. Johnson RW Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648 [TBL] [Abstract][Full Text] [Related]
11. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. Langan SM; Smeeth L; Margolis DJ; Thomas SL PLoS Med; 2013; 10(4):e1001420. PubMed ID: 23585738 [TBL] [Abstract][Full Text] [Related]
12. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study. Oh H; Tan C; Williams C; Giannelos N; Ng C Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600 [TBL] [Abstract][Full Text] [Related]
13. Vaccination against herpes zoster in developed countries: state of the evidence. Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. Hoshi SL; Kondo M; Okubo I Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176 [TBL] [Abstract][Full Text] [Related]
15. Herpes zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in New Zealand: a retrospective cohort study. Mbinta JF; Wang AX; Nguyen BP; Paynter J; Awuni PMA; Pine R; Sporle AA; Simpson CR Lancet Reg Health West Pac; 2023 Feb; 31():100601. PubMed ID: 36879782 [TBL] [Abstract][Full Text] [Related]
16. Herpes Zoster and Postherpetic Neuralgia: Changing Incidence Rates From 1994 to 2018 in the United States. Thompson RR; Kong CL; Porco TC; Kim E; Ebert CD; Acharya NR Clin Infect Dis; 2021 Nov; 73(9):e3210-e3217. PubMed ID: 32829399 [TBL] [Abstract][Full Text] [Related]
17. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856 [TBL] [Abstract][Full Text] [Related]
18. Public health impact of herpes zoster vaccination on older adults in Hong Kong. Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records. Klein NP; Bartlett J; Fireman B; Marks MA; Hansen J; Lewis E; Aukes L; Saddier P BMJ; 2023 Nov; 383():e076321. PubMed ID: 37940142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]